Letter

POPADAD trial

Time for a proper study of aspirin after a vascular event?

BMJ 2008; 337 doi: 10.1136/bmj.a2583 (Published 19 November 2008)
Cite this as: BMJ 2008;337:a2583

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. John G F Cleland, professor of cardiology1
  1. 1Castle Hill Hospital, University of Hull, Kingston upon Hull HU16 5JQ
  1. j.g.cleland{at}hull.ac.uk

    Belch et al add to the documentation that long term aspirin has little or no benefit in patients who have or are at risk of atherosclerotic cardiovascular disease.1 2

    Few long term trials of aspirin have shown a reduction in mortality or major morbidity. However, editors of journals persist in publishing papers on aspirin with conclusions designed to mislead health professionals and the public.

    The New …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular